•
Mar 31, 2022
Coherus Q1 2022 Earnings Report
Reported financial results for the quarter ended March 31, 2022.
Key Takeaways
Coherus BioSciences reported a net revenue of $60.1 million, primarily from UDENYCA® sales, and a net loss of $96.1 million for the first quarter of 2022. The company is preparing for multiple product launches and continues to invest in its immuno-oncology pipeline.
CIMERLI™ BLA review is progressing toward an August 2022 action date.
Toripalimab BLA resubmission is expected by mid-summer.
UDENYCA® delivered net sales of $60.1 million in Q1 2022.
2022 R&D and SG&A expense guidance was reduced by $20 million.
Coherus
Coherus
Forward Guidance
Coherus is lowering the projected range for combined full year 2022 R&D and SG&A expenses by $20 million to $395 million to $430 million.